Combination of Imipridone ONC201 or ONC206 with Temozolomide and Radiotherapy in triple ITR therapy reduces intracranial tumor burden and prolongs survival in an orthotopic wild-type IDH GBM mouse model

Lanlan Zhou,Leiqing Zhang,Jun Zhang,Laura Jinxuan Wu,Shengliang Zhang,Andrew George,Marina Hahn,Howard P. Safran,Clark C. Chen,Attila A. Seyhan,Eric T. Wong,Wafik S. El-Deiry

DOI: https://doi.org/10.1101/2024.09.25.610187

2024-09-27

Abstract:Glioblastoma remains the most lethal common primary brain tumor in adults with limited therapeutic options. TIC10/ONC201, a first-in-class imipridone we discovered, achieved meaningful therapeutic effects in phase I/II trials in patients with diffuse gliomas harboring H3K27M mutations, and currently the drug is in randomized phase III testing (ACTION trial; ). ONC201 targets mitochondrial protease ClpP to disrupt oxidative phosphorylation and trigger the integrated stress response (ISR), TRAIL/DR5, and tumor cell death. We hypothesized that ONC201 and its analogue ONC206 synergize with temozolomide (TMZ) and ionizing radiation (IR), standard-of-care glioblastoma therapies. ONC201 enhances TMZ or IR-induced apoptosis, and cytotoxicity. ClpP-silencing suppresses ONC201-induced cytotoxicity but not TMZ or RT. Both ONC201 and ONC206 reduce expression of TMZ-resistance mediator MGMT. Suppression of MGMT protein was observed in H3K27M-mutated DIPG cell lines following treatment with ONC201 or ONC206 with or without TMZ. Cytokine profiling indicates distinct ONC201 alterations relative to TMZ suggesting distinct anti-tumor immune mechanisms. Triple IR+TMZ+ONC201 (ITR) therapy prolongs median survival to 123 days with a tail on survival curve (3-of-7 mice alive beyond 200-days) in an orthotopic U251 GBM model versus ONC201 (44-days; p=0.000197), IR (63-days; p=0.0012), TMZ (78-days; p=0.0354), ONC201+IR (55-days; p=0.0004), ONC201+TMZ (80-days; p=0.0041) and IR+TMZ (103-days; p>0.05). By 231-days, the only surviving mice were in IRT group. Our results support investigation of ONC201/ONC206 in combination with TMZ and IR (ITR) in GBM or H3K27M mutated diffuse glioma therapy.

Cancer Biology

What problem does this paper attempt to address?

The problems that this paper attempts to solve are: How to improve the treatment effect of glioblastoma (GBM), prolong survival and reduce tumor burden by jointly using Imipridone - class drugs ONC201 or ONC206 and standard treatment methods (temozolomide TMZ and radiotherapy RT).

Specifically, the researchers hope to verify the following hypotheses:

1. **Whether the combined treatment of ONC201 or ONC206 with TMZ and RT (referred to as ITR therapy) can act synergistically**, thereby more effectively inhibiting tumor growth, inducing apoptosis, and prolonging the survival of patients.
2. **Whether this combined treatment is effective in IDH - wild - type GBM mouse models**, especially for those patients who respond poorly to traditional treatment.
3. **Whether ONC201 or ONC206 can enhance the efficacy of TMZ by inhibiting the expression of MGMT protein** (a DNA repair protein related to TMZ resistance).

### Summary of main research questions:
- **Improving GBM treatment effect**: Explore the synergistic effect of the combined use of ONC201 or ONC206 with TMZ and RT, in order to significantly improve the prognosis of GBM patients.
- **Mechanism exploration**: Study how ONC201 or ONC206 enhances the anti - tumor effect by activating the integrated stress response (ISR) and other pathways (such as ClpP activation, ROS production, etc.).
- **Clinical translation potential**: Evaluate the potential value of this combined treatment regimen in clinical applications, especially for diffuse midline gliomas with H3K27M mutations (such as DIPG).

Through these studies, the authors hope to provide a new and more effective treatment strategy for GBM and other related brain tumors.